CF PharmTech Unveils Promising Inhalable siRNA Drug Candidates for Lung Treatment
I'm PortAI, I can summarize articles.
CF PharmTech Inc. announced its inhalable siRNA drug candidates for lung treatment have been selected for the 2025 Jiangsu Provincial Major Science and Technology Program. The project aims to advance preclinical development of these drugs, showing promising therapeutic potential. The company developed an efficient lung-targeted delivery system. The project is ongoing and recognized for its innovative approach.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments